Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.

Asset List(PDF) Asset List by Disease Area(PDF) Asset List(Excel)

Date Candidate Mechanism of action Indication Route Modality Development stage Note
03/01/19 GEM066 Selective STAT3 inhibitor (DNA-based Decoy) Head and neck squamous cell carcinoma and non-small cell lung cancer [including exon 20 mutations] IV Nucleic acids
Pre-IND for systemic administration formulation 1st-in-class STAT3 decoy;
Suppresses binding of STAT3 to genomic DNA;
Inhibits proliferation and promotes apoptosis of many cancer cells;
Suppresses expression of STAT3 target genes and tumor growth in animal models;
Shows increased response in combination with cetuximab and also with PD-1;
Human Phase 0 study (intratumor injection); Suppresses STAT3 target genes expression with one dose
Does not affect normal oral keratinocytes;
Exploratory animal toxicology studies show no significant adverse effects;
Contact
03/01/19 GEM064 Selective inhibitor of Nav channels Pain Oral Small molecule
Preclinical Potent and selective inhibitors for Nav 1.7/1.8 subtypes
Effective in inflammatory & neuropathic pain states
Exellent non-clinical ADMET profile
No off-target activity, very good in vitro cardiac safety margin, non-mutagenic
Contact
02/12/19 GEM063 Novel 24hr ibuprofen patch Local pain in sprains Local Small molecule
Phase 1 completed High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove
Pre-clinical safety studies were completed 2017 with no concerns/issues
Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues
Contact
01/11/19 GEM009 BET inhibitor Cancer, RA Oral Small molecules
Preclinical Updated on January 11, 2019

More potent enzyme inhibition and anti-tumor activities compared with competitors (more potent than GSK525762A and comparble to ABBV-075).
Superior safety profile than competitors (no inhibition on hERG or CYP3A4) and can be applied to RA.
Easier manufacturing due to absence of asymmetric carbon.
Contact
01/11/19 GEM003 Selective glucocorticoid receptor agonist RA/OA, Please refer to Note Local Small molecules
Preclinical Updated on January 11, 2019

Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation)
Discontinued development for RA/OA. Available for repositioning.
Possible indications: Atopic dermatitis, Psoriasis, Asthma, COPD, Inflammatory bowel disease etc.
Contact
01/11/19 GEM002 Kappa-opioid receptor agonist Pain/Itching, Please refer to Note Oral Small molecules
Preclinical Updated on January 11, 2019

Discontinued development for pain because of company strategy. Available for repositioning.
Possible indications: Chronic pains (Back pain, Arthritis pain, Cancer pain, Post-herpetic neuralgia, Trigeminal neuralgia etc), Pruritus, Irritable bowel syndrome
Contact
01/11/19 GEM001 TRPV-1 agonist Rheumatoid Arthritis, Please refer to Note Oral Small molecules
Phase 2a Updated on January 11, 2019

Potently inhibits TNF-a production by oral administration.
Discontinued development for RA. Available for repositioning.
Possible indications: Neuropathic pain, Crohn’s disease, Systemic lupus erythematosus, Cachexia, Acute infectious disease, Allergy, Pyrexia, Anemia, Diabetes, Diseases related TNF-α (Colitis, Psoriasis ets.)
Contact
01/07/19 GEM062 Cannabinoid-releasing topical formulation (siustained release for about 24 hours) Chronic pain, Sclerosis, Lupus, others Topical Small molecule
Preclinical Cannabinoid’s utility: nausea and vomiting during chemotherapy, chronic pain, muscle spasms, epilepsy, sclerosis, lupus, schizophrenia etc.
This sustained-release topical formulation has significant potential to help treat these disorders. Preclinical efficacy demonstrated in a cutaneous lupus rodent model using AEA.
Contact
01/07/19 GEM061 Curcumin-releasing topical formulation (sustained release for about 24 hours) Please refer to Note Topical Small molecule
Preclinical Indication:
Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell)

Note:
Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes.
This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model.
Contact
01/07/19 GEM060 Nitric Oxide-releasing topical formulation (sustained release for over 48 hours) Please refer to Note Topical Small molecules
Preclinical Indication:
Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others

Note:
NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc.
Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers.
This formulation breaks through the limitations of sustained NO (topical) delivery.
Contact